MyFinsight
Home
Blog
About
Net income (loss)
$15,009K
(194.48%↑ Y/Y)
Proceeds from issuance of
common stock pursuant...
$1,629K
(23.50%↑ Y/Y)
Proceeds from issuance of
common stock upon...
$1,361K
(2131.15%↑ Y/Y)
Stock-based compensation
expense
$12,762K
(21.67%↑ Y/Y)
Accrued liabilities
$9,955K
(-53.11%↓ Y/Y)
Amortization of intangible
assets
$563K
(0.00%↑ Y/Y)
Non-cash interest
expense
$480K
(11.37%↑ Y/Y)
Other non-cash items,
net
-$277K
(20.40%↑ Y/Y)
Net cash provided by
(used in) operating...
$12,639K
(3800.93%↑ Y/Y)
Net cash provided by
financing activities
$1,990K
(44.20%↑ Y/Y)
Canceled cashflow
$26,407K
Canceled cashflow
$1,000K
Net increase
(decrease) in cash, cash...
-$641K
(-103.32%↓ Y/Y)
Canceled cashflow
$14,629K
Proceeds from maturities
and sales of...
$50,525K
Accounts payable
-$11,536K
(-2182.31%↓ Y/Y)
Accounts receivable, net
$10,786K
(-49.29%↓ Y/Y)
Prepaid expenses and
other current assets
$2,546K
(159.21%↑ Y/Y)
Inventory
$1,177K
(327.22%↑ Y/Y)
Net accretion on
marketable securities
$223K
(-67.91%↓ Y/Y)
Operating lease
liabilities
-$139K
(31.86%↑ Y/Y)
Payment of debt
prepayment penalty
$1,000K
Net cash provided by
(used in) investing...
-$15,224K
(-187.38%↓ Y/Y)
Canceled cashflow
$50,525K
Effect of exchange rate
changes on cash
-$46K
(-123.00%↓ Y/Y)
Purchases of marketable
securities
$65,591K
(97.85%↑ Y/Y)
Purchases of property and
equipment
$158K
(102.56%↑ Y/Y)
Back
Back
Cash Flow
logo-arcutis (1)-svg
Arcutis Biotherapeutics, Inc. (ARQT)
logo-arcutis (1)-svg
source: myfinsight.com
Arcutis Biotherapeutics, Inc. (ARQT)